FDA Advice on Labeling, Advertising Biologics Updated in Revised Draft Guidance

Answers to questions biologics companies may have when developing promotional communications for prescription biologics including reference products, biosimilars, and interchangeable biosimilars have been issued by the FDA in a revised draft guidance.
Source: Drug Industry Daily